B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioNote Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Cash from Financing Activities
-â‚©49.9B
CAGR 3-Years
-62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash from Financing Activities
-â‚©273.9B
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
-18%
SK Bioscience Co Ltd
KRX:302440
Cash from Financing Activities
-â‚©89.6B
CAGR 3-Years
-288%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash from Financing Activities
-â‚©181.7B
CAGR 3-Years
-91%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Financing Activities
-â‚©17.7B
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Financing Activities
â‚©33.2B
CAGR 3-Years
-42%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
469.5B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
6 138.02 KRW
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Cash from Financing Activities?
Cash from Financing Activities
-49.9B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Cash from Financing Activities amounts to -49.9B KRW.

What is BioNote Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-62%

The average annual Cash from Financing Activities growth rates for BioNote Inc have been -62% over the past three years .

Back to Top